Selicrelumab 

Selicrelumab is an agonist CD40 antibody, induces changes in the tumor microenvironment. Selicrelumab can be used for the research of pancreatic cance and neoadjuvant study^[1].

Human IgG2 kappa

Human IgG2 kappa, Isotype Control

Human

Selicrelumab (10 µg/mL, 2-3 days) activates the CD40 receptor on chronic lymphocytic leukemia (CLL) cells, upregulates co-stimulatory molecules (CD86), cytokines (TNF-α) and death receptors (CD95) in primary CLL cells^[2].
Selicrelumab (10 µg/mL, 2 days) promotes the expression of anti-apoptotic protein MCL-1, induces resistance to Venetoclax (HY-15531) in CLL cells^[2].
Selicrelumab (10 µg/mL, 2 days) enhances the sensitivity of CLL cells to GA101 (HY-P9910)-induced cell death through a lysosome-mediated mechanism^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

146.2 kDa

1622140-49-1

Liquid

Colorless to light yellow

[Selicrelumab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG2 kappa

• [1]. Katelyn T Byrne, Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Clin Cancer Res. 2021 Aug 15;27(16):4574-4586.  [Content Brief]

  [2]. Delgado R, et al., Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia. Cancers (Basel). 2021 Jun 21;13(12):3084.  [Content Brief]